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INTRODUCTION
More than 25% of deaths among Japanese are attributed to arte-
riosclerotic disease, such as myocardial infarction and cerebral
infarction (1). Brought on by atherosclerosis, arteriosclerotic disease
is a coronary artery disease which is closely related to dyslipide-
mia. To prevent arteriosclerotic disease, managing risk factors,
such as high blood pressure, diabetes, and chronic kidney disease
(CKD), not to mention dyslipidemia, has been shown to be effec-
tive (2). Modifications in eating habits and exercise habits have
constituted the chief methods to improve these risk factors. For
cases that cannot be controlled by these methods, treatment by
drugs has been relied on. Instruction on meals to adjust eating
habits has been tried, but due to the difficulty in complying with
such instructions, its effectiveness has not been satisfactory. More
aggressive measures that use food and its ingredients are being
pursued.
It is well known that the intake of whole grains, such as brown
rice (BR), improves lipid metabolism (3). Pre-germinated brown
rice (PGBR) is rice which has been slightly germinated by soak-
ing BR in water. PGBR is being widely supplied throughout Japan.
The content of protein, carbohydrate, dietary fiber, vitamins and
minerals in PGBR is the same as that of BR, but the process of
germination has increased components such as gamma-amino
acid (GABA) and acylated steryl glucosides (ASG). The effective-
ness of PGBR on lipid abnormality and glucometabolic abnor-
mality confirmed in tests on animal models and on humans has
been reported (4-11). Moreover, it has been confirmed that the
ASG fraction extracted from PGBR bran promoted the activity of
homocystine thiolactone hydroxylase (HTLase) in diabetic rats
(12). The authors have also confirmed that the lipid metabolism
of diet - induced obese mice is improved by feeding with ASG frac-
tion extracted from rice bran (manuscript in preparation). When
ASG fraction extracted from rice bran was added to AIN-93G for-
mula with the carbohydrate source changed from corn starch to
WR and this feed was fed to Senescence-accelerate mice (SAM)
P8 for 18 weeks, an improvement in lipid metabolism compared
to the WR diet was observed (manuscript in preparation). ASG
fraction is contained in the bran of PGBR and BR, but it is not con-
tained in the white rice that Asians prefer to eat. Therefore, ASG
fraction is considered to be one of the important effective compo-
nents of BR, particularly of PGBR.
We can anticipate the improvement of dyslipidemia by the intake
of ASG fraction, but the effectiveness of its intake by humans has
not been confirmed. We have obtained rice bran extract contain-
ing ASG fraction (RB-ASG). We examined whether or not RB-
ASG decreases blood LDL cholesterol (LDL-C) level in obese
Japanese men.
MATERIALS AND METHODS
Setting and study subjects.
The protocol of this study was approved by the institutional re-
view board at FANCL Corp. before being conducted. All subjects
were fully informed about the nature and methods of the studies,
and informed consent was obtained in compliance with the Dec-
laration of Helsinki. The subjects were volunteers recruited via
third party institutions and unrelated to the authors’ affiliated in-
stitution. The study utilized a randomized, double-blind design.
Eligibility criteria were Japanese obese (BMI25 kg/m2) men
aged 40 years or older with blood LDL-C level120 mg/dL. Major
exclusion criteria include the following : Those who were being
treated by doctors for some medical problems and those who were
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regularly taking medication ; those who were suffering from serious
heart disease, brain disease, kidney disease, liver disease, gastro-
intestinal disease and their complications ; those who were using
pace-makers and those who did not feel well due to sudden changes
in weight two months after the start of the test. 104 subjects par-
ticipated in the screening test. Of these, 60 participated in the
test.
They were divided into the two groups as follows, with care
taken that there was no bias with respect to age, gender, BMI or
blood LDL-C : a RB-ASG group (n=40) and a Placebo group (n=
20). The subjects in the RB-ASG group received 30-50 mg/day of
RB-ASG, and the Placebo (corn oil) group took 9 capsules/day
for 12 weeks. All participant and capsule provider were blinded to
the intervention. We used FANCL-manufactured PSG for RB-
ASG. All subjects were asked to avoid modifying their lifestyle dur-
ing the study. We instructed the subjects not to intake any phar-
maceuticals or food that claimed cholesterol -reduction action, in-
hibitory action for the rise of triacylglycerol (TG), or body-fat -
reduction action during for the duration of the study.
All the tests were conducted at Kenkoin Medical Corporation
Foundation. We carried out measurements, blood collection and
the surveys on meals before the start of intake (baseline) and after
intake (final). For the day before the test, we instructed the subjects
not to smoke and to have their specified evening meal (consisting
of meat and potato stew, hijiki (a kind of brown algae) and soybean
stew, simmered ostrich fern and rice, totaling 614 kcal) by hour 21
and to have no food thereafter ; only water was allowed. On the
day of the test, we required the subjects to fast all day, until the
end of the test. Only water was allowed. All measurements were
conducted in the morning. Placebo group and RB-ASG group were
mesured on same day.
Anthropometrical measurements.
Visceral fat area, subcutaneous fat area and abdominal circum-
ference were determined by abdominal computed tomography
(CT). Body fat percentage was measured by dual -energy x-ray
absorptiometry. We calculated BMI, using the already-reported
calculation formula.
Blood collection.
Total cholesterol (TC), HDL cholesterol (HDL-C), TG, glucose
and HbA1c (NGSP) levels in the blood were measured. We cal-
culated LDL-C/HDL-C (LH) ratio using the already-reported
calculation formula.
Diet survey.
We used a brief - type self -administered diet history question-
naire (BDHQ) for the diet surveys (13).
Statistical analyses.
What constituted the primary outcome measure of our evalu-
ation was the percent change in LDL-C at baseline and final. What
constituted the items of our secondary evaluation were TC, HDL-
C, TG, BMI, visceral fat area, subcutaneous fat area, abdominal
circumference and body fat percentage. We calculated the percent
change of the final versus the baseline for each items evaluated.
We calculated the percent change of the final versus the baseline
for each items evaluated. The percent change in the RB-ASG group
and the Placebo group were compared using the unpaired t- test.
The final and the baseline data in the RB-ASG group and the Pla-
cebo group were compared using the paired t- test. Items with con-
firmed homoscedasticity were compared by Student’s t - test and
those with no confirmed homoscedasticity using Welch’s t - test.
P-values of less than 0.05 were considered statistically significant
for all the analyses. The above statistical procedures were per-
formed using JMP version8 (SAS Institute Inc., North Carolina).
RESULTS
Subjects.
Of the 60 subjects, 4 from the RB-ASG group and 1 from the
Placebo group withdrew from the test either before or after the
start of their ingestion period, due to personal reasons. Moreover,
2 from the RB-ASG group and 2 from the Placebo group were
excluded from the analysis, because the results of their basal test
did not meet the selection criteria. As a result, the number of sub-
jects in the analysis was 51. All subjects compliance were90%.
During the period of the test, neither group developed subjective
symptoms related to the intake of the testing substances.
Baseline characteristics.
We show the background of the subjects in Table 1. Compared
to that of the RB-ASG Group, HbA1c of the Placebo group was
significantly higher, but both groups were within the reference
range. No significant difference was observed in other parameters.
Energy and nutrient intakes.
We show the intake amount of energy and nutritional composi-
tion in Table 2. Between the two groups, there was no significant
difference in the intake amount of energy and nutritional compo-
sition at the respective times of baseline and final.
Table 1. Comparison of physical characteristics and blood biochemi-
cal parameters between ASG and Placebo groups at baseline.
RB-ASG Placebo Total
Age (year) 52 8 56 8 54 8
BMI (kg/m2) 28.1 3.0 27.1 2.2 27.8 2.7
Body fat (%) 31.7 5.3 28.7 4.2 30.7 5.1
Systolic blood
pressure (mmHg) 142.9
16.4 143.6 15.4 143.1 15.9
Diastolic blood
pressure (mmHg) 90.1
11.3 91.6 11.9 90.6 11.4
Abdominal
circumference (cm) 95.1
8.1 92.4 7.7 96.9 7.7
Visceral fat area
(cm2) 158.1
39.8 160.4 62.6 158.8 47.9
Subcutaneous fat
area (cm2) 195.7
87.2 163.5 51.7 185 78.2
Total cholesterol
(mg/dL) 244.7
31.8 246.8 24.3 245.4 29.3
non HDL cholesterol
(mg/dL) 194.8
31.9 193.1 24.3 194.2 29.4
LDL cholesterol
(mg/dL) 165.4
29.0 163 24.1 164.6 27.3
HDL cholesterol
(mg/dL) 49.9
11.1 53.8 14.3 51.2 12.3
LDL-C/HDL-C ratio 3.5 1.0 3.2 0.9 3.4 1.0
Triacylglycerol
(mg/dL) 159.4
82.0 174.8 85.7 164.5 82.8
HbA1c (%) 5.5 0.3 * 5.8 0.4 5.6 0.4
Values are meansSD for 34 (RB-ASG) or 17 (Placebo) subjects.
*Significant difference between RB-ASG and Placebo group by unpaired
t - test at p0.05.
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Physical characteristics.
In Table 3, we indicate the physical characteristics of the two
groups at the times of baseline and final. No significant difference
was observed between the groups in BMI or body fat percentage
from baseline to final. In the RB-ASG group, the abdominal cir-
cumference improved significantly from baseline to final ; the sub-
cutaneous fat area also improved significantly. Moreover, the vis-
ceral fat area changed, showing a significant tendency to improve
(p=0.09). As for percentage change for abdominal circumference
and subcutaneous fat area of the RB-ASG group, there was sig-
nificant improvement, compared to that of the Placebo group.
Blood biochemical parameters.
In Table 4, we show the blood biochemical parameters of the
RB-ASG group and the Placebo group at the time of baseline and
final. No significant difference was observed between HDL-C and
TG. In the RB-ASG group, LDL-C dropped significantly from base-
line to final. TC and non HDL-C also dropped significantly. The
LH ratio also improved significantly from baseline to final. In the
RB-ASG group, the percentage change from baseline to final im-
proved quite significantly, compared to that of the Placebo group
LDL-C, TC, non HDL-C, LH ratio. In Figure 1, we show the indi-
vidual changes and average levels of LDL-C for each subject.
DISCUSSION
The results of this study suggest that the intake of RB-ASG
improved the blood LDL cholesterol level of humans who were
obese and who had high LDL cholesterol. Moreover, the body
perimeter and the subcutaneous fat area of the RB-ASG group
also improved very significantly, compared to those of the Placebo
group. In this study, we made the intake amount of RB-ASG 30-
50 mg/day, but this is an amount equivalent to 300 to 500 g (2-3
servings) of boiled PGBR. In a study that has been conducted on
Taiwanese (10) and Vietnamese subjects (11), we observed an
improvement in lipid metabolism and a reduction in body circum-
ference by switching the staple food from WR to PGBR in their
three meals per day. It may be possible to explain part of PGBR’s
lipid metabolism action and body-perimeter-reduction action by
RB-ASG which contained PGBR.
Regarding phytosterol, which is an important component of RB-
ASG, an LDL-C reduction effect has been reported (14, 15). It has
been reported that in human subjects whose cholesterol level was
between a normal range and a somewhat high range, having them
intake margarine that contained 1.5 to 3.3 g/day of plant sterol
for 3.5 weeks led to the result of their LDL-C decreasing to 13%
from 8% (14). It may be possible to explain part of the RB-ASG
improvement action on lipid metabolism that was confirmed in




RB-ASG 2073.3 963.1 2025.9 809.3
Placebo 1932.0 701.3 2048.9 711.0
Lipid (g)
RB-ASG 56.9 31.1 60.2 31.1
Placebo 57.7 22.5 60.3 25.8
Protein (g)
RB-ASG 73.4 33.6 70.9 28.5
Placebo 72.6 26.5 76.2 27.9
Carbohydrate (g)
RB-ASG 282.1 118.9 269.8 109.5
Placebo 257.7 109.6 271.3 113.1
Fiber (g)
RB-ASG 11.6 4.9 11.3 5.2
Placebo 12.1 4.2 11.3 3.4
Values are meansSD for 34 (RB-ASG) or 17 (Placebo) subjects.
Table 3. Physical characteristics at final in ASG and Placebo groups.
Final Percent change (%)
BMI RB-ASG 27.9 27.9 -0.7 2.2
(kg/m2) Placebo 27.1 27.1 0.0 1.7
Body fat RB-ASG 31.9 4.9 0.9 4.7




(cm) Placebo 92.6 7.0 -0.9 2.6
Visceral fat area RB-ASG 151.0 40.8 -4.1 14.4
(g/cm2) Placebo 160.9 55.7 2.1 11.5
Subcutaneous
fat area RB-ASG 188.0
82.9# -3.6 7.5*
(g/cm2) Placebo 164.1 48.2 1.6 8.7
Values are meansSD for 34 (RB-ASG) or 17 (placebo) subjects.
* Significant difference compared to Placebo by unpaired t - test ; p0.05
# Significant difference compared to baseline by paired t - test ; p0.05
Table 4. Blood biochemical parameters at final in RB-ASG and Pla-
cebo groups.
Final Percent change (%)
Total cholesterol RB-ASG 226.9 29.0# -6.7 10.2*
(mg/dL) Placebo 245.6 33.5 -0.6 8.4
LDL cholesterol RB-ASG 145.2 24.0# -11.2 12.4*
(mg/dL) Placebo 160.4 24.1 -1.3 9.2
non HDL cholesterol RB-ASG 176.5 28.3# -8.6 11.5*
(mg/dL) Placebo 190.2 28.9 -1.4 8.8
HDL cholesterol RB-ASG 50.4 10.8 1.7 12.3
(mg/dL) Placebo 55.4 18.1 2.4 9.9
Triacylglycerol RB-ASG 164.2 71.8 12.1 41.1
(mg/dL) Placebo 170.1 83.1 1.3 28.0
LDL-C/HDL-C ratio
RB-ASG 3.0 0.7# -12.0 13.7*
Placebo 3.1 0.9 -3.4 6.2
Values are meansSD for 34 (RB-ASG) or 17 (Placebo) subjects.
* Significant difference compared to Placebo by unpaired t - test ; p0.05
# Significant difference compared to baseline by paired t - test ; p0.05
Figure 1 Serum LDL cholesterol level at baseline and final.
Bold Line : mean for 34 (RB-ASG) or 17 (Placebo) subjects. Thin line :
individual data.*Significant difference compared to baseline by paired t -
test ; p0.05
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this study as the effect of phytosterol. However, the intake amount
of RB-ASG (30 to 50 mg/day) was low, compared to the intake
amount of phytosterol that was reported in the margarine study.
In experiments that used animal models, Lin et al have reported on
the importance of ASG that had undergone acylation, by comparing
it with steryl glucosides (16). The amount of cholesterol discharged
in the excrement was found to increase from the intake of ASG.
The current study did not clearly reveal the mechanism of ASG
fraction, but it may be no different from what had been reported
by Lin et al.
The results of the abdominal CT test revealed that the percent-
age change in the subcutaneous fat area and body perimeter of
the RB-ASG group was significantly greater, compared with that
of the Placebo group. The visceral fat area showed the tendency
to decrease after intake only in the RB-ASG group. The fact that
the decrease was in the fat area led us to believe that it contrib-
uted to the reduction of diabetes, dyslipidemia, high blood pres-
sure and, by extension, arteriosclerotic disease, for which obesity
constituted a risk factor. Furthermore, the reductions of the vis-
ceral fat area and the subcutaneous fat area, as well as the rate of
change in body perimeter, were interrelated. On the other hand,
no changes were observed in BMI and body fat percentages. It is
also conceivable that the intake duration of three months was
too short to clearly perceive weight reduction resulting from the
composition of food being consumed, without guidance on special
meals and exercise. According to the dietary survey, the final en-
ergy intake of the Placebo group rose by 5.7% compared to the
baseline. In this study, one month within a three-month interven-
tion period was targeted for the dietary survey. Therefore the
results may not necessarily reflect the dietary content for the entire
intervention period. Moreover, subcutaneous fat areas of the Pla-
cebo group showed lower than those of the RB-ASG group, though
not significantly. To clarify the decrease in subcutaneous fat areas
due to RB-ASG intake, investigation based on a strict dietary survey
and a longer intervention period may be necessary.
However, this study clearly confirmed that the intake of RB-ASG
improved the blood LDL cholesterol level of people who were
obese and who had high LDL cholesterol. Many epidemiological
studies conducted in Japan have confirmed the continuous rise in
the relative risks of arteriosclerotic disease, along with the rise in
LDL-C (17-21). In addition, it has been shown that arteriosclerotic
disease was controlled by intervention in high LDL-C by using
pravastatin (22-24). Moreover, many epidemiological studies have
elucidated that non HDL-C, which is the index obtained by sub-
tracting HDL-C from TC, is related to arteriosclerotic disease.
There are also reports that have indicated that non HDL-C is su-
perior to LDL-C as the index for forecasting the onset of arterio-
sclerotic disease, because it contains remnant lipoprotein that
causes arteriosclerosis. In this study, non HDL-C also decreased
significantly by the intake of RB-ASG. The intake of RB-ASG has
the potential to reduce the risk of developing arteriosclerotic dis-
ease mainly by improving LDL-C and non HDL-C.
From this study, we can conclude that the ingestion of RB-ASG
for three months suggested its potential to contribute to the im-
provement of blood lipids of those with dyslipidemia.
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